Charles River Laboratories International Inc. (CRL) News
Filter CRL News Items
CRL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CRL News Highlights
- CRL's 30 day story count now stands at 13.
- Over the past 21 days, the trend for CRL's stories per day has been choppy and unclear. It has oscillated between 1 and 6.
- LAB, BIO and CDMO are the most mentioned tickers in articles about CRL.
Latest CRL News From Around the Web
Below are the latest news stories about CHARLES RIVER LABORATORIES INTERNATIONAL INC that investors may wish to consider to help them evaluate CRL as an investment opportunity.
Charles River (CRL) to Build RightSource Lab With New PactCharles River (CRL) will establish a CGMP testing lab at Wheeler's factory through latest partnership. |
Wheeler Bio and Charles River Laboratories Announce Agreement to Build and Operate RightSource(SM) LaboratoryWheeler Bio, Inc., a contract development and manufacturing organization (CDMO), and Charles River Laboratories International, Inc. (NYSE: CRL) today announced an agreement to implement RightSourceSM at Wheeler Bio's current good manufacturing practice (cGMP) biologics manufacturing facility in Oklahoma City, OK. Deployed on-site at a client's facility, RightSourceSM is a flexible biologics testing lab operated and managed by Charles River, making fast, reliable quality control (QC) more accessi |
Charles River Laboratories and Wheeler Bio Announce Agreement to Build and Operate RightSourceSM LaboratoryWILMINGTON, Mass., May 31, 2023--Charles River Laboratories International, Inc. (NYSE: CRL) and Wheeler Bio, Inc., a contract development and manufacturing organization (CDMO), today announced an agreement to implement RightSourceSM at Wheeler Bio’s current good manufacturing practice (CGMP) biologics manufacturing facility in Oklahoma City, OK. Deployed on-site at a client’s facility, RightSource is a flexible biologics testing lab operated and managed by Charles River, making fast, reliable qu |
Here's Why You Should Retain Charles River (CRL) Stock NowCharles River's (CRL) share price is likely to grow, backed by strategic acquisitions and the DSA segment's strength. |
3 DNA Stocks to Buy for the Synthetic Biology RevolutionSynthetic biology is a growing industry. |
Declining Stock and Solid Fundamentals: Is The Market Wrong About Charles River Laboratories International, Inc. (NYSE:CRL)?It is hard to get excited after looking at Charles River Laboratories International's (NYSE:CRL) recent performance... |
Q1 2023 Charles River Laboratories International Inc Earnings CallQ1 2023 Charles River Laboratories International Inc Earnings Call |
Charles River Laboratories Stock Ticks Higher, Tightens FY23 Outlook On Strong Q1 PerformanceCharles River Laboratories International Inc (NYSE: CRL) reported Q1 sales of $1.03 billion, an increase of 12.6% Y/Y, beating the consensus of $986.35 million. The company reported adjusted EPS of $2.78, beating the Wall Street estimate of $2.59. Acquisitions contributed 1.8%, and the divestiture of the Avian Vaccine business in December 2022 reduced reported revenue growth by 2.5%. The impact of foreign currency reduced reported revenue growth by 2.1%. Organic revenue growth of 15.4% was drive |
Charles River (CRL) Q1 Earnings Top Estimates, View NarrowedCharles River (CRL) registers robust growth in small research models, research model services and the Cell Solutions business. |
Charles River beats profit estimates on strength in drug discovery servicesCharles River Laboratories International Inc beat Wall Street estimates for first-quarter profit on Thursday, due to strong demand for its services that help clients discover new drug candidates and assess their safety. The contract research company reported revenue of $662.4 million in its discovery and safety assessment (DSA) segment, higher than analysts' average estimate of $610.9 million, according to Refinitiv data. Wilmington, Massachusetts-based Charles River said it believes its biotech clients have the funds required to take the development of their drug candidates forward, pointing to the robust demand for its DSA unit services. |